Drugs / Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection
Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06880419 | Mar → Dec 2025 overdue | acute graft versus host disease | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06880419 ↗ |
| Modality | Monoclonal antibody | “Recombinant humanized anti-CD25 monoclonal antibody” NCT06880419 ↗ |